Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.310
-0.240 (-9.41%)
At close: Apr 7, 2026, 4:00 PM EDT
2.406
+0.096 (4.16%)
After-hours: Apr 7, 2026, 7:59 PM EDT
Esperion Therapeutics Revenue
In the year 2025, Esperion Therapeutics had annual revenue of $403.14M with 21.31% growth. Esperion Therapeutics had revenue of $168.45M in the quarter ending December 31, 2025, with 143.73% growth.
Revenue (ttm)
$403.14M
Revenue Growth
+21.31%
P/S Ratio
1.47
Revenue / Employee
$1,371,207
Employees
294
Market Cap
593.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 403.14M | 70.82M | 21.31% |
| Dec 31, 2024 | 332.31M | 215.98M | 185.66% |
| Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
| Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
| Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
| Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
| Dec 31, 2019 | 148.36M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 887.40M |
| Tilray Brands | 858.28M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Ironwood Pharmaceuticals | 296.15M |
| Kamada | 180.46M |
| Cronos Group | 146.59M |
ESPR News
- 5 days ago - Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - GlobeNewsWire
- 5 days ago - Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - GlobeNewsWire
- 22 days ago - Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - GlobeNewsWire
- 4 weeks ago - Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Business Wire
- 6 weeks ago - Esperion to Participate in The 2026 Citizens Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 - GlobeNewsWire
- 7 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire